Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Involving transferase

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435016000 Involving transaminase 8
435017000 Involving creatine phosphokinase 6
Entries
DocumentTitleDate
20110201038METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.08-18-2011
20080274486Method of Assaying Fad Synthetase - The present invention relates to methods of determining activity of flavin adenine dinucleotide (FAD) synthetase, and methods of identifying compounds that modulate the activity of this enzyme.11-06-2008
20100015650KINASE SUBSTRATES - Tyrosine kinase substrates are described herein that are phosphorylated by many and diverse tyrosine kinases, and are chemically stable relative to co-polymers of poly-EY or poly-EAY having random molecular weights in the range of 20-50 kDa. Tyrosine kinase substrate peptides are provided according to embodiments described herein which include an isolated tyrosine kinase substrate peptide having molecular weight in the range of about 0.5 kD-10 kD. Tyrosine kinase substrate peptides are provided according to embodiments described herein having no more than 50 amino acids. The peptides include 2-25 phosphorylation modules and each phosphorylation module has 2-3 amino acid residues.01-21-2010
20090191579ANALGESIA WITH MINIMAL TOLERANCE AND DEPENDENCE BY A MU OPIOID RECEPTOR AGONIST THAT ALSO BINDS FILAMIN A - A composition and method are disclosed that utilize an isolated polypeptide or analog thereof to inhibit the interaction of a mu-opioid receptor with filamin A. A contemplated polypeptide has an amino acid residue sequence illustrated by the formula: W-[X07-30-2009
20090191578Canis sphingosine 1-phosphate receptor isoform 5 - A Canis sphingosine-1-phosphate (S1P) receptor isoform 5 (cS1P07-30-2009
20090305318Diagnostic Tests of Substance Use Disorders - The present invention relates to compositions and methods for identifying and quantifying platelet proteins. As certain behaviors and medical conditions alter the quantity of various platelet membrane proteins, the tools of the present invention are suitable for identification of biomarkers of these bodily states. For instance, the present invention provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies.12-10-2009
20100047835DIAGNOSIS OF INFECTIONS OR INFLAMMATORY DISEASES OF THE AIRWAYS AND LUNGS ASSOCIATED WITH HEART FAILURE - The invention relates to a method for diagnosis of infections or inflammatory diseases of the airways and lungs with associated heart failure, wherein the marker procalcitonin or a partial sequence thereof is determined in a patient to be examined, in particular for classifying patients according to risk. The invention further relates to a diagnostic device and kit for carrying out the method.02-25-2010
20130078660METHODS AND COMPOSITIONS FOR DETECTING PROTEIN MODIFICATIONS - Methods and compositions for detecting a protein modification in vitro and in vivo are disclosed. In certain embodiments, the protein modification detected is phosphorylation.03-28-2013
20100112617Evaluating RTK Target Drugs - Methods of evaluating receptor tyrosine kinase drug efficacy are demonstrated. The methods generally relate to evaluation methods using phospho-RTK over total RTK ratio (pRTK/tRTK). An algorithm is provided that allows the user to combine the pRTK/tRTK ratios from several kinase together with other kinds of measurements to obtain a PDX value that is indicative of drug efficacy.05-06-2010
20100075354MARKER FOR IDENTIFICATION OF TISSUE TYPE OF EPITHELIAL OVARIAN CANCER, AND METHOD FOR DETERMINATION OF THE OCCURRENCE OF EPITHELIAL OVARIAN CANCER BASED ON TISSUE TYPE BY USING THE MARKER - It is provided a method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type in view of molecular typing which is different from a conventional histopathology, and a marker for identification of a tissue-type of epithelial ovarian cancer. A method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type, comprising: subjecting a sample originated from an individual of interest to a treatment for detecting at least one selected from the group consisting of biological molecules specifically showing an upregulation in expression in a specific tissue-type of epithelial ovarian cancer, and/or at least one selected from the group consisting of biological molecules specifically showing a downregulation in expression in a specific tissue-type of epithelial ovarian cancer, and identifying whether or not the significant detection of the protein is achieved, thereby identifying the tissue-type.03-25-2010
20130040327Methods for Identifying Allosteric and Other Novel Acyl-Coenzyme A:Cholesterol Acyltransferase Inhibitors - The present invention is a method for identifying compounds that are allosteric and/or other novel ACAT inhibitors that is based on the novel finding that pregnenolone is a substrate for ACAT; esterification of pregnenolone by ACAT is dramatically activated when cholesterol is present in the assay. The method comprises measuring the esterification of pregnenolone by ACAT under two different conditions: with cholesterol, or without cholesterol. This method can be used to test and categorize various candidate ACAT inhibitors as allosteric or other novel ACAT inhibitors, or it can be used in high-throughput screening for identifying such ACAT inhibitors.02-14-2013
20090181415PREDICTION OF GENOTOXICITY - The likelihood that a compound will exhibit genotoxicity in a micronucleus test is predicted by the ability of the compound to inhibit a plurality of kinases from a selected group.07-16-2009
20100099126METHOD OF CALCULATING ENZYMATIC REACTION RATE, COMPUTER PROGRAM PRODUCT AND METHOD OF DETERMINING AMOUNT OF ENZYME IN SAMPLE - A method of calculating an enzymatic reaction rate using the largest frequency value of a slope of a sub-group, a computer program product capable of performing the method of calculating an enzymatic reaction rate, and a method of determining the amount of an enzyme in a sample are provided.04-22-2010
20090162881METHOD OF MEASURING ADENINE NUCLEOTIDE - A high sensitivity electrochemistry type method for measuring adenine nucleotide which has a convenient and further miniaturized measuring device structure; is low in consumptive power; and does not require a treatment operation for substances that cause turbidity is provided. A method for measuring adenine nucleotide, which comprises a step A for converting adenosine triphosphate to adenosine diphosphate by an enzyme E06-25-2009
20130045498VISCOSITY PRESSURE ASSAY - The present invention relates to methods of determining enzyme activity in a fluid, wherein the activity over time provides a viscosity-change in the fluid, by the use of a device (FIG. 02-21-2013
20090155828METHODS OF DETECTING PROSTATE CANCER - Proteins specific for prostate epithelial cells, normal or neoplastic, are identified and used for diagnosis, development of antibodies, and for evaluating drugs that react with the neoplastic specific proteins. Affinity based probes are used that react specifically with the active site to provide a measure of the enzyme activity of the cells. Prostate epithelial neoplastic cells can be used in screening candidate drugs for their effect in changing the proteome profile as to the serine-threonine hydrolase enzymes, using the affinity based probes for determining the profile.06-18-2009
20090155827PIGF and FLT-1 as Prognostic Parameters for Cardiovascular Diseases - The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use.06-18-2009
20100105092LIPOLYTIC ENZYME VARIANTS - Variants with increased acyl transferase activity can be designed on the basis of a three-dimensional model by making amino acid alterations near the active Ser of lipolytic enzymes such as 04-29-2010
20100041085Methods and kits for assaying acetyl transferase or deacetylase activity - The invention provides methods and kits for characterizing the activity of an acetyl transferase or deacetylase. The method involves enzymatically acetylating or deacetylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically acylating the peptide substrate with acyl groups that differ in molecular weight from the enzymatically added or removed acetyl groups. Typically, deuterated acetic anhydride is used to non-enzymatically acylate the substrate. The fully acylated substrate is then characterized by mass spectrometry to determine the amino acid positions of the substrate that are enyzmatically acetylated or deacetylated.02-18-2010
20090136978 METHOD FOR MEASURING PHOSPHORIC ACID - In measuring phosphoric acid by the use of an enzyme cycling system using a dehydrogenase together with a thio-NADP, a thio-NAD, a reduced thio-NADP or a reduced thio-NAD as a coenzyme, phosphoric acid is measurable in a wide concentration range from a low concentration to a high concentration by measuring phosphoric acid after previous removal of free phosphoric acid in reagent components for the measurement.05-28-2009
20090117599METHOD OF DETECTING SUGAR CHAINS HAVING GlcNAc TRANSFERRED BY GnT-V - It is intended to provide a method by which sugar chains having GlcNAc transferred by GnT-V can be accurately detected, screened and purified. In this detection method, two kinds of lectins differing in detailed GlcNAc-specificity are used together. As shown in FIG. 05-07-2009
20100136592Photo-Induced Damage Mitigating Agents and Preparation and Methods of Use Thereof - Compositions, devices, systems and methods for reducing and/or preventing photo-induced damage of one or more reactants in an illuminated analytical reaction by addition of one or more photo-induced damage mitigating agents to the reaction mixture and allowing the reaction to proceed for a period that is less than a photo-induced damage threshold period.06-03-2010
20090104638Methods for Building Atomic Models of Protein Molecules and Determining Drug Candidates Using MGST1 - Methods for building an atomic model of a protein molecule comprising: (a) identifying a protein molecule with at least 20% sequence identity with Microsomal Glutathione Transferase 1 (MGST1) and (b) utilizing the atomic coordinates of MGST1 to obtain an atomic model of the identified protein molecule and methods for determining a drug candidate compound that interacts with members of the MAPEG superfamily, in particular MGST1 are also provided.04-23-2009
20130137125CRYSTAL STRUCTURE OF HUMAN JAK3 KINASE DOMAIN COMPLEX AND BINDING POCKETS THEREOF - The present invention relates to human Janus Kinase 3 (JAK3) and JAK3-like binding pockets. The present invention provides a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to JAK3 protein or JAK3 protein homologues, or complexes thereof. The invention also relates to crystallizable compositions and crystals comprising JAK3 kinase domain and JAK3 kinase domain complexes with AMP-PNP.05-30-2013
20130089882Chloroacetamidine Based Inhibitors and Activity Based Probes for the Protein Arginine Methytransferases - In accordance with certain embodiments of the present disclosure, a protein arginine methyltransferase inhibitor is provided. The inhibitor comprises an amino acid peptide joined to a chloroacetamidine warhead.04-11-2013
20130059319METHOD AND A DEVICE FOR DETECTING, CLASSIFYING, AND IDENTIFYING PARTICLES, AEROSOLS, AND/OR VAPORS IN THE AIR - A method and device are disclosed for continuously detecting, classifying and identifying toxic particles, aerosols and/or vapor in an air sample, in near real time by directing an air sample containing an optional target analyte, in the form of particles, aerosols and/or vapors, enzyme(s), and enzyme substrate(s), to a surface of a collection matrix for forming a biocatalytic reaction product of a plurality of freely mobile optical reporters, and by using a light source with optical reader to interpret the signal from the optical reporter, enabling the detection, classification and identification of toxic particles, aerosols and/or vapor in the air sample.03-07-2013
20130065262PHOSPHATASE COUPLED GLYCOSYLTRANSFERASE ASSAY - A kit for detecting or measuring glycosyltransferase activity including a first reagent comprising a phosphatase and a second reagent comprising a free phosphate detector, and method of detecting and measuring glycosyltransferase activity. A sugar donor, an acceptor substrate, a glycosyltransferase enzyme and a phosphatase are combined and the amount of free phosphate present in the product is measured and used to calculate the activity of the glycosyltransferase enzyme.03-14-2013
20090047696DETECTION OF INFECTIOUS PRION PROTEIN BY SEEDED CONVERSION OF RECOMBINANT PRION PROTEIN - The present disclosure relates to methods and compositions for the detection of infectious proteins or prions in samples, including the diagnosis of prion related diseases. One embodiment is an ultrasensitive method for detecting PrP-res (PrP02-19-2009
20090047694Clinical Intervention Directed Diagnostic Methods - The invention provides methods for assessing the clinical status of a patient. In particular, the invention provides methods for identifying the presence of or likelihood of disease or disease recurrence. In practice, methods of the invention provide the ability to screen patients into one of three distinct clinical categories. Based upon measurement of clinically-relevant biomarkers in a sample obtained from a patient, the invention allows the unambiguous identification of patients who are not at risk for or do not have the relevant disease, the unambiguous identification of patients at increased risk or who have the disease; and the identification of patients who should receive standard of care treatment and/or monitoring. Use of the invention maximizes the number of patients who will receive accelerated intervention or monitoring and minimizes those patients who will receive unnecessary standard of care or accelerated intervention or monitoring.02-19-2009
20120115176METHOD FOR DETECTING COMPOUNDS MODULATING DIMERS OF VFT DOMAIN MEMBRANE PROTEINS - The invention relates to a method for selecting compounds having a modulating effect on the activation state of a dimer of VFT-domain proteins expressed in cell membranes present in a measuring medium, said dimer consisting of a first protein and of a second protein, said proteins being identical or different, wherein this method comprises the following steps: 05-10-2012
20090029399METHOD FOR RAPID DETERMINATION OF THIOPURINE METHYLTRANSFERASE ACTIVITY - This document provides methods and materials related to rapid, quantitative determination of TPMT activity in biological samples. Also featured are compositions and kits useful for determination of TPMT activity in biological samples.01-29-2009
20100086955Small Molecule Inhibitors of Ghrelin O-Acyltransferase - Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules. Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition.04-08-2010
20120237961Labelling of Fusion Proteins with Synthetic Probes - The invention relates to new proteins called alkylcytosine transferases (ACTs) derived from O09-20-2012
20120064555QUANTITATIVE ANALYSIS OF A BIOLOGICAL SAMPLE OF UNKNOWN QUANTITY - Disclosed is a method for testing a modified specimen such as a dried blood spot, plasma or serum specimen, for an analyte of interest, such as cholesterol. In accordance with the disclosed subject matter, the level of the analyte of interest in the medium from which the modified specimen was obtained (e.g., from a patient's blood) is determined based on the level of an analyte in a solution formed from the modified specimen and on the level of at least one normalizing analyte. The analyte and normalizing analyte each may be an ion, compound, biochemical entity, or property of the specimen. Also disclosed are a fluid collector and a fluid collection device.03-15-2012
20110281290SOX-BASED KINASE SENSOR - Peptidyl sensors comprise a metal-binding peptide and one or two kinase recognition sequences with a hydroxyamino acid that can be phosphorylated in the presence of a kinase.11-17-2011
20110281289QUANTIFICATION OF ENZYME ACTIVITY BY MASS SPECTROMETRY USING IMMOBILIZED SUBSTRATES - The disclosure relates to methods of analyzing the enzymatic activity of enzymes in samples containing a plurality of enzymes, using mass spectrometry. Immobilized substrates are employed. Purified enzymes and enzymes from crude cell lysates can be analyzed using the disclosed methods.11-17-2011
20110281288Reusable Nanowire Field Effect Transistor System for Detecting Biomolecular Interactions - A reusable nanowire field effect transistor for detecting biomolecular interactions. The field effect transistor contains nanowire covalently linked to a docking molecule, which is capable of binding to an anchor molecule in a reversible manner, i.e., at an association constant of 1011-17-2011
20110124021PHOSPHORYLATED FATTY ACID SYNTHASE AND CANCER - The disclosed invention relates to the detection of phosphorylated fatty acid synthase as a diagnostic and a component in the identification and treatment of cancer. The disclosed methods permit early and accurate diagnosis of cancer to enable more effective therapy and to enhance patient survival and quality of life.05-26-2011
20090111134Multiplex PCR Assay For Identification of USA300 and USA400 Community-Associated Methicillin Resistant Staphylococcal Aureus Strains - The present invention relates to multiplex polymerase chain reaction (PCR) assays for 04-30-2009
20080318264Biomarkers Associated With Age-Related Macular Degeneration - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD.12-25-2008
20110287462PROTEIN FRAGMENT COMPLEMENTATION ASSAY FOR THERMOPHILES - A protein fragment complementation assay for thermophiles is provided wherein a thermophilic bacteria having a temperature-sensitive adenylate kinase is transformed with one or more vectors having sequences encoding a first test peptide operatively fused to a first portion of a thermostable adenylate and a second test peptide operatively fused to a second portion of the thermostable adenylate kinase. Association of the first and second test peptides allows association of the first and second portions of the thermostable adenylate kinase and growth of the thermophilic bacteria at a temperature greater than 70° C.11-24-2011
20090170142USE OF 4'-PHOSPHOPANTETHEINYL TRANSFERASE AS A TARGET FOR IDENTIFYING ANTIBIOTIC MOLECULES - The present invention pertains to the use of a PptT protein, as a target for screening compounds for identifying those having an antibiotic activity, especially against a pathogenic bacterium containing mycolic acids. The invention also concerns an in vitro screening process for identifying compounds having an antibiotic activity, by measuring the activity of a PptT protein in the presence or absence of said compounds.07-02-2009
20120270250TEST SYSTEM FOR MEASURING MEST ACTIVITY AS WELL AS METHODS AND USES INVOLVING THE SAME - The present invention relates to a test system for measuring MEST activity, a method for screening for a ligand for MEST and the use of the test system for the identification of a MEST ligand, particularly a MEST inhibitor.10-25-2012
20090181414RETENTATE CHROMATOGRAPHY AND PROTEIN CHIP ARRAYS WITH APPLICATIONS IN BIOLOGY AND MEDICINE - This invention provides methods of retentate chromatography for resolving analytes in a sample. The methods involve adsorbing the analytes to a substrate under a plurality of different selectivity conditions, and detecting the analytes retained on the substrate by desorption spectrometry. The methods are useful in biology and medicine, including clinical diagnostics and drug discovery.07-16-2009
20100035289DIAGNOSIS AND RISK STRATIFICATION BY MEANS OF THE NOVEL MARKER CT-PROADM - The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No, 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method.02-11-2010
20090093006Core 2 Beta(1,6)-Acetylglycosaminyltransferase as Diagnostic Marker for Atherosclerosis - A method of indicating the presence of the atherosclerosis (particularly coronary artery atherosclerosis) in a subject is provided, comprising comparing the level of Core 2 GlcNAc-T in a tissue sample from a subject with a reference level determined for the same tissue. A level of Core 2 GlcNAc-T in the tissue sample from a subject that is higher than that of the reference level being indicative that the subject is afflicted with atherosclerosis (particularly coronary artery atherosclerosis—coronary artery disease—CAD). In preferred embodiments, the sample consists of leukocytes and the protein level is determined as the enzymatic activity using radiolabeled UDP-GlcNAc and a Galβ(1,3)-GalNAc derivative.04-09-2009
20090148876METHODS FOR THE GENERATION OF CARTILAGE-LIKE MATERIAL BY MECHANICAL LOADING - A cartilage-like biomaterial is bioengineered by using a self-aggregating suspension cell culture with hydrostatic mechanical force without the use of a scaffold or foreign matrix for cell attachment during culture. The cells in suspension culture may be preconditioned prior to application of the hydrostatic mechanical force, such as hydrostatic pressure, for a period of time in the range of about 1 week to about 10 weeks. The cartilage-like biomaterial shares critical structural, phenotype, and functional characteristics with native, intact cartilage tissue.06-11-2009
20100267067Synthase Inhibitor Screening Method - The present invention relates to a method for selecting at least one host cell secreting one or more active enzyme of interest, said method comprising the steps of: a) providing a growth medium comprising one or more synthase inhibitor, which inhibits the synthesis of at least one essential compound in the host cell, and further comprising one or more component, which in the presence of the one or more active enzyme of interest is converted into the at least one essential compound, thereby allowing the host cell to grow; b) cultivating the host cell in or on the growth medium of step (a); and c) selecting at least one host cell capable of growing in or on the growth medium of step (a), which host cell secretes one or more active enzyme of interest.10-21-2010
20090004683Indicator Agent for Noninflammatory Stress Response and Use Thereof - A system enabling the molecular biological visualization and quantitative detection of events in a stress-exposed living organism and a means enabling the management of stress are provided. An indicator agent for non-inflammatory stress responses mediated by superoxide, which comprises IL-18, a visualizing agent for non-inflammatory stress responses for detecting the aforementioned indicator agent, a method of measuring the degree of non-inflammatory stress, which comprises using the aforementioned visualizing agent, a method of preventing, ameliorating or predicting a change in immune status based on a non-inflammatory stress response, which comprises applying the aforementioned visualizing agent to an animal, and a therapeutic agent for a change in immune status based on a non-inflammatory stress response for reducing the amount or activity of the aforementioned indicator agent.01-01-2009
20110195439SYSTEMS AND METHODS FOR DETERMINING CARDIAC CONDITIONS - Systems and methods for determining cardiac conditions. According to at least one embodiment of a stabilizing system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for cardiovascular disease in a body fluid comprising the diagnostic marker and a detection agent capable of detecting the diagnostic marker.08-11-2011
20090311731Modified Molecule - We describe a microbial cell, typically a bacterial cell, genetically engineered to produce a modified sugar nucleotide, for example UDP glucuronic acid, and the use of the modified sugar to transfer glucuronic acid to small acceptor molecules.12-17-2009
20100086956DETECTION OF HIV-RELATED PROTEINS IN URINE - A method for detecting HIV infection in a mammal is disclosed. The method contains the steps of isolating exosomes from a urine sample of a mammal and detecting the presence of HIV-specific biomarker in said isolated exosomes. A method for diagnosing a mammal with an HIV-associated disease, in particular, HIV-associated nephropathy is also disclosed.04-08-2010
20100081153CANCER ASSOCIATED PROTEIN KINASES AND THEIR USES - Detection of expression of the provided protein kinase in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and determining patient prognosis. The encoded polypeptides further provides a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells.04-01-2010
20120107852METHOD FOR PREPARING MODIFIED POLYPEPTIDES - Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve 05-03-2012
20090246809METHOD OF SUPPORTING A DIAGNOSIS OF A RISK OF CANCER RECURRENCE, AND A DEVICE OF SUPPORTING A DIAGNOSIS OF A RISK OF CANCER RECURRENCE - A method of supporting a diagnosis of a risk of cancer recurrence is disclosed. The method provides a new determining value a recurrence risk score (RRS) which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The risk of cancer recurrence is judged by comparing the RRS with a predetermined threshold level for RRS.10-01-2009
20090263841USE OF NNMT AS A MARKER FOR LUNG CANCER - The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.10-22-2009
20110201037USE OF ERYTHROPOIETIN TO DEVELOP SMALL MOLECULE INHIBITORS OF JANUS KINASE-2 - The invention pertains to a method for identifying compounds that inhibit the erythropoietin-induced JAK2 kinase activity in vivo. The present invention provides a method for detecting small molecule JAK2 inhibitors in a rapidly created rodent model that phenocopies human PV through Epo stimulation. The method comprises the steps of (a) dosing a rodent with erythropoietin (Epo) and a test compound, (b) collecting blood samples after the dose is administered, (c) measuring phosphorylated STAT5 levels in the blood sample, and (d) determining JAK2 inhibitor levels in the blood samples.08-18-2011
20090286269Method for detecting PrP using at least one positive charge and/or at least one glycosidic bond and a ligand other than a protein ligand - A method for detecting PrP in a biological human or animal sample that may contain said PrP. The method is characterized in that it uses a molecule containing at least one positive charge and/or at least one glycosidic bond and a ligand other than a protein ligand selected from macrocyclic ligands and glycosaminoglycans.11-19-2009
20090111135METHOD AND APPARATUS FOR DIAGNOSES OF HEMANGIOSARCOMA IN MAMMALS - The disclosure relates to a method for detecting hemangiosarcoma in canines. The method includes the steps of: (1) obtaining a quantity of blood from the subject canine; (2) separating the quantity of blood into a serum portion and a non-serum portion; (3) contacting the serum portion of the blood with a detector to detect presence of an amount of Thymidine Kinase (TK); and (4) detecting the level of TK in serum and determining whether TK is present in amounts of about 8 units/mL or greater.04-30-2009
20100136593METHOD FOR DIAGNOSING AND DISTINGUISHING STROKE AND DIAGNOSTIC DEVICES FOR USE THEREIN - A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.06-03-2010
20100279327METHOD OF TREATING DISEASES WITH PARP INHIBITORS - The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a sample of a subject, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in the subject with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors. The present invention also relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in a subject population with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors.11-04-2010
20100143956PREDICTIVE RENAL SAFETY BIOMARKERS AND BIOMARKER SIGNATURES TO MONITOR KIDNEY FUNCTION - Biomarker signatures were identified which can be used to diagnose or predict kidney or liver toxicity and more specifically renal tubular toxicity as a consequence of disease or drug treatment.06-10-2010
20080274487Use of Serum/Glucocorticoid-Regulated Kinase - The invention relates to the use of an SGK protein, a functional derivative or fragment thereof, or a nucleic acid coding for one such protein, fragment or derivative, in order to discover active ingredients for the prevention or treatment of degenerative cartilage changes.11-06-2008
20100227350Method of Screening Substance Useful in Treating Disease With the Use of GPR40 and Phospholipase - The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.09-09-2010
20080280314Devices and methods for profiling enzyme substrates - The present invention relates to apparatus and methods for separating and detecting enzyme substrates using separation gels. For example, the apparatus and methods can be used to separate and detect kinase substrates for further analysis. The apparatus and methods can also be used to detect enzyme inhibitors, such as kinase inhibitors.11-13-2008
20080280313Coccidian Parasite Casein Kinase I as a Chemotherapeutic Target for Antiprotozoal Agents - Isolated nucleic acid molecules encoding coccidian casein kinase I, CKI, enzymes from the species 11-13-2008
20080305507METHODS AND COMPOSITIONS FOR ASSAYING HOMOCYSTEINE - This invention relates generally to the field of homocysteine detection. In particular, the invention provides a method for determining homocysteine presence or concentration in samples, which method comprises: contacting a sample containing or suspected of containing Hcy with a Hcy co-substrate and a Hcy converting enzyme in a Hcy conversion reaction to form a Hcy conversion product and a Hcy co-substrate conversion product; and assessing the Hcy co-substrate conversion product to determine the presence, absence and/or amount of the Hcy in the sample. The Hcy co-substrate conversion product may be assessed directly, or it may be assessed by further conversion of the Hcy co-substrate conversion product into another material by the action of one or more additional enzymes. A kit for assaying homocysteine based on the same principle is also provided.12-11-2008
20080206800Method for Measuring Tyrosine Kinase Phosphorylation - Method, kit and composition for measuring the autophosphorylation of one or more tyrosine kinases in presence of a kinase inhibitor compared to the absence of said kinase inhibitor for kinase specificity profiling of kinase inhibitors.08-28-2008
20110207157Labelling of Fusion Proteins With Synthetic Probes - The invention relates to new proteins called alkylcytosine transferases (ACTs) derived from O08-25-2011
20090061469Methods and kits for assaying acetyl transferase or deacetylase activity - The invention provides methods and kits for characterizing the activity of an acetyl transferase or deacetylase. The method involves enzymatically acetylating or deacetylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically acylating the peptide substrate with acyl groups that differ in molecular weight from the enzymatically added or removed acetyl groups. Typically, deuterated acetic anhydride is used to non-enzymatically acylate the substrate. The fully acylated substrate is then characterized by mass spectrometry to determine the amino acid positions of the substrate that are enzymatically acetylated or deacetylated.03-05-2009
20100273195SKIN AGING-PREVENTING OR IMPROVING AGENT - The present invention provides a skin aging-preventing or improving agent. The agent contains a substance capable of enhancing the expression level of Rho kinase or myosin light-chain kinase. According to the present invention, aging of the skin such as sagging of the skin, wrinkle formation, or loss of skin elasticity can be prevented or the skin can be improved.10-28-2010
20110269161Methods, Compositions and Kits for High Throughput Kinase Activity Screening Using Mass Spectrometry and Stable Isotopes - A mass-spectrometry-based method and substrates are provided herein for large scale kinome activity profiling directly from crude lysates using 90 chemically synthesized peptide substrates with amino acid sequences derived from known phosphoproteins. Quantification of peptide phosphorylation rates was achieved via the use of stable isotope labeled synthetic peptides. Half of these peptides immediately or rapidly showed robust and site-specific phosphorylation after incubation with serum-starved HEK293 cell lysate. A method and substrates for obtaining 90 simultaneous activity measurements in a single-reaction format were developed and validated. Activating kinase pathways through insulin or EGF stimulation reproducibly altered the phosphorylation rates of peptides derived from known pathway protein substrates. While examining cell-cycle-specific activities with the panel, a peptide derived from phosphoinositide 3-kinase regulatory subunit demonstrated mitotic and tyrosine-specific phosphorylation, which was confirmed to be a Src kinase site in vivo. The kinome activity profiling strategy was successfully applied with lysates of each of: cells manipulated by various combination of mitogen stimulation, pharmacological perturbation and siRNA-directed kinase knockdown; seven different breast cancer cell lines treated with gefitinib; and each of normal and cancerous tissue samples from renal cell carcinoma patients. This method concurrently measures multiple peptide phosphorylation rates to provide a diagnostic fingerprint pattern for activated kinases, protein phosphatases, modulators of these enzymes, and pathways (kinome) from as little starting material as a few cells.11-03-2011
20090142784METHODS - A method for identifying a compound expected to be useful in modulating a LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a LRRK2 polypeptide on a substrate Ezrin/Radixin/moesin (ERM) family polypeptide and (2) selecting a compound which modulates the LRRK2 polypeptide protein kinase activity. Such a compound may be useful in treating Parkinson's Disease or Parkinsonism. A catalytically active fragment of LRRK2 is identified, requiring the GTPase, COR and kinase domains as well as the WD_40-like motif and C-terminal tail.06-04-2009
20080318263METHOD OF IDENTIFYING CANCER BIOMARKERS AND CANCER PROGRESSION - An efficient method for identifying important cancer biomarkers and identifying progression of bladder cancer using pro-u-PA as a clinical tool is provided. Searching for biomarkers critical for bladder carcinoma diagnosis and prognosis, secreted proteomes of highly malignant U1 and pre-malignant U4 cell lines are first analyzed. Proteins in the cultured media of the U1 and U4 cell-lines were systematically examined by SDS-PAGE combined with MALDI-TOF mass spectrometry. Expression of pro-u-plasminogen activator (pro-u-PA) was confirmed by Western blot analysis and further evaluated. A statistically significant relationship between the low level and absence of pro-u-PA in urine with high stages and grades of the tumor samples was established. Constitutive expression of Ras dominant negative protein led to increased expression of pro-u-PA in cultured media, indicating the loss of pro-u-PA is associated with oncogenic transformation. The loss of pro-u-PA in urine has been identified as a marker of more advanced bladder carcinoma.12-25-2008
20080318262Protein Cleavage at Aspartic Acid Using Chemical Reagents - The present invention relates to the methods of identifying and quantifying polypeptides in a given sample by mass spectrometric analysis. More specifically, the invention provides the methods for sample preparation for proteomic analysis: the methods for the fragmentation of proteins into peptides with the specific cleavage rule (cleavage at amino-terminal or carboxyl-terminal of aspartic acid), which are suitable for the analysis by mass spectrometry apparatus.12-25-2008
20120244567HUMAN EMBRYONIC STEM CELLS FOR HIGH THROUGHOUT DRUG SCREENING - Methods of culturing embryonic stem cells in a format suitable for high-throughput screening (HTS) are provided. In addition compounds that show differential cytotoxic/protective activity on embryonic stem cells (ESCs) and neurological stem cells (NSCs) are provided.09-27-2012
20120244566Methods and materials for in vitro analysis and/or use of membrane-associated proteins, portions thereof or variants thereof - Methods and materials use template-directed assembly of polypeptides and optionally additional reagents to analyze the functionality of membrane-associated proteins, such as, for example, portions of transmembrane proteins, membrane-associated proteins (including receptor tyrosine kinases, and non-receptor tyrosine and serine-threonine kinases), and other proteins that bind to transmembrane proteins and membrane-associated proteins, and to analyze the effect of test compounds or mutations on the functionality of same. The methods and materials of the present application provide a more native-like environment for analyzing the functionality of membrane-associated proteins, and thus provide effective tools for studies involving the detection of the level of enzyme activity of such proteins in an environment that closely resembles the native environment in the cell, and for novel manufacturing processes.09-27-2012
20090117598Method for identifying compounds that affect a transport of a protein through a membrane trafficking pathway - The present invention relates to a method for identifying compounds that affect a transport of a receptor of interest through a specific membrane trafficking pathway mediated by said receptor within the context of a generic membrane trafficking pathway, which generic pathway is not mediated by said receptor, characterised by the following steps: 05-07-2009
20090208990HUMAN PROTEIN ACYL TRANSFERASES AND METHODS OF USES THEREFOR - The present invention provides the identification of human Ras palmitoyl acyl transfersase complexes, and nucleic acids coding therefor. In addition, methods of screening for modulators of human Ras palmitoyl acyl transfersase, including high throughput yeast screens, are also provided.08-20-2009
20090208991Prediction of bone marrow toxicity - The likelihood that a compound will exhibit bone marrow toxicity in an in vivo assay predicted by the ability of the compound to inhibit at least eight kinases from a selected group.08-20-2009
20080261256Methods of assaying receptor activity and constructs useful in such methods - Described are methods of detecting G-protein coupled receptor (GPCR) activity in vivo and in vitro; methods of assaying GPCR activity; and methods of screening for GPCR ligands, G protein-coupled receptor kinase (GRK) activity, and compounds that interact with components of the GPCR regulatory process. Constructs useful in such methods are described.10-23-2008
20080261255Proteins, Sensors, and Methods of Characterizing Analytes Using the Same - A protein sensing molecule is capable of binding an analyte in a sample. The protein sensing molecule includes a first detectable quality that changes in a concentration dependent manner when the protein sensing molecule is bound to the analyte. The protein sensing molecule also includes a second detectable quality that does not undergo substantial change when the protein sensing molecule is bound to the analyte. The protein sensing molecule may be used in methods for characterizing samples and may also be used in sensors.10-23-2008
20090253156MASS SPECTROMETRY METHODS FOR MULTIPLEXED QUANTIFICATION OF PROTEIN KINASES AND PHOSPHATASES - The inventions relates to methods and kits for capture and/or analysis of kinases and/or phosphatases in one or more samples. In some embodiments, a kinase inhibitor, e.g. staurosporine or its derivative, is used to capture kinases from a sample. In some embodiments, a phosphatase inhibitor, e.g. microcystin or its derivative, is used to capture phosphatases from a sample. Methods for quantitative analysis of captured kinases and/or proteases are also provided. In some embodiments, quantitative analysis is accomplished using mass spectrometry. In addition, the invention provides kits related to same.10-08-2009
20090253157METHOD OF DIRECTED DIFFERENTIATION OF PORCINE EMBRYONIC STEM CELLS AND USING THE SAID CELLS IN DRUG SCREENING - The present invention relates to a method of directed differentiation of porcine embryonic stem cells into specific neural lineages. The present invention also relates to a method for identifying neurogenic stimulator using the said porcine embryonic stem cells.10-08-2009
20100184107PROTEIN TRAFFICKING - The present invention relates, in general, to protein trafficking, and, in particular, to a method of measuring protein trafficking to and from a plasma membrane.07-22-2010
20080213811SENSOR PROTEINS AND ASSAY METHODS - The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.09-04-2008
20100151505METHODS FOR MODULATING THERMOSTABILITY AND ACID TOLERANCE OF MICROBES - The present invention relates a method for modulating thermostability or acid tolerance of a microbe, comprising the steps of: (a) conferring a substitution mutation to a homoserine o-succinyltransferase (MetA)-encoding nucleotide sequence; and (b) transforming the MetA-encoding nucleotide sequence into a microbial cell. The mutated MetA of the present invention shows stability notably enhanced at high-temperatures and/or under acid conditions or decreased at mild temperature, and the microbe, particular bacteria expressing the mutated MetA of the present invention represents a growth rate improved in a vigorous environment such as higher-temperatures and/or lower acid conditions.06-17-2010
20090170141GHRELIN O-ACYLTRANSFERASE (GOAT) BIOCHEMICAL ASSAY - Ghrelin is acylated ghrelin O-acyltransferase. Ghrelin O-acyltransferase assays comprise contacting a mixture of ghrelin and recombinant ghrelin O-acyltransferase with an agent; and detecting a resultant decrease in acylation of the ghrelin by the acyltransferase.07-02-2009
20100240080KINASE AND PHOSPHATASE ASSAYS - Compositions, methods, and kits for detecting and monitoring kinase, phosphatase and protein post-translational modification activity are described. The compositions typically include a peptide, a detectable moiety, and a protease cleavage site. Modification of a peptide by a kinase, phosphatase or other protein post-translational modification alters the proteolytic sensitivity of the peptide, resulting in a change of a detectable property of the composition. Panel assays for determining substrates or modulators of kinase, phosphatase or other protein post-translational modification activity are also described.09-23-2010
20100227349USE OF LYMPHOCYTES TO MEASURE ANTHRAX LETHAL TOXIN ACTIVITY - It is disclosed herein that isolated lymphocytes, such as human B-cells and CD409-09-2010
20100240081SEPRASE AS A MARKER FOR CANCER - The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.09-23-2010
20130217055METHOD FOR PREDICTING TYROSINE KINASE INHIBITOR (TKI) RESISTANCE IN PATIENTS SUFFERING FROM CHRONIC MYELOGENOUS LEUKEMIA (CML) - The present invention relates to a method for determining or predicting the response of a patient diagnosed with chronic myelogenous leukaemia (CML) to treatment with a tyrosine kinase inhibitor. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof thereby diagnosing CML patients resistant to treatment with Imatinib.08-22-2013
20100112616NOVEL BETA-GALACTOSIDE-a2,6-SIALYLTRANSFERASE, A GENE ENCODING THEREOF, AND A METHOD FOR ENHANCING ENZYME ACTIVITY - The present invention provides an extremely useful and novel β-galactoside-α2,6-sialyltransferase having an optimum reaction pH in a neutral to alkaline range, and a nucleic acid encoding the sialyltransferase. The present invention further provides a vector carrying a nucleic acid encoding the sialyltransferase, and a host cell transformed with the vector, as well as a method for producing a recombinant β-galactoside-α2,6-sialyltransferase.05-06-2010
20090075313Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems - Split protein herpes simplex virus type 1 thymidine kinase [HSV1-TK or TK] TK fragments, split protein TK systems, methods of imaging protein-protein interactions, methods of cellular localization of proteins, methods of evaluating protein translocation and trafficking, and the like, are provided. In addition, the present disclosure includes compositions used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging) in vivo and in vitro.03-19-2009
20090075311ASSESSING COLORECTAL CANCER BY MEASURING HEMOGLOBIN AND M2-PK IN A STOOL SAMPLE - The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is, for example, practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of hemoglobin and M2-PK and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer in a method of this invention the level of one or more additional marker may be determined together with hemoglobin and M2-PK in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising hemoglobin and M2-PK in the early diagnosis of colorectal cancer, and it teaches a kit for performing the method of the invention.03-19-2009
20100221763Specific Acceptors for Transferases to Saccharides and Method for Obtaining and Using Same - A method for determining substrates specific for a transferase enzyme selected from the group consisting of glycosyltransferases and sulfotransferases. The method includes the steps of: 09-02-2010
20090176264Calibrator/Control for Simultaneous Assay of Proteins Capable of Complexing With One Another - Disclosed herein are compositions and methods comprising two or more proteins in which at least one of the proteins has been altered to reduce their mutual recognition and binding. Such compositions are useful as reference, calibrators or controls in methods and assays for determining the amount of one or more of the proteins that may be present in a sample of interest or in confirming the presence of one or more of the proteins in the sample. More particularly, it relates to compositions and methods comprising altered placental growth factor-1 (PlGF-1) and soluble fms-like tyrosine kinase (sFlt-1) and methods for determining the amount or confirming the presence of sFlt-1 and/or PlGF-1 in a sample of interest.07-09-2009
20090111137SIMULTANEOUS DETECTION OF METABOLIC ENZYME ACTIVITY AND METABOLITE LEVELS - Provided are methods for detecting a metabolic disorder in an individual using mass spectrometry. One method involves (a) contacting a sample containing (i) one or more metabolically indicative enzymes and (ii) one or more metabolic analytes, with one or more substrates for said one or more enzymes to produce a reaction admixture, under conditions wherein at least one of said enzymes is capable of acting on a corresponding substrate to generate at least one product, and wherein one or more protease inhibitors are present; (b) contacting said reaction admixture with a reagent that inhibits the ability of said one or more enzymes to act on a corresponding substrate, wherein said one or more metabolic analytes and said at least one product are soluble in said reagent; to produce a test sample and (c) determining the presence or amount of said one or more metabolic analytes and said at least one product contained in said test sample using mass spectrometry, wherein a determined presence or amount of said one or more metabolic analytes and said at least one product correlates with presence or absence of said metabolic disorder product correlates with presence or absence of said metabolic disorder.04-30-2009
20090111136METHOD FOR DETECTION, DETERMINATION OR PREDICTION OF HEPATIC DISORDER - The invention relates to a method for examining a hepatic disorder (e.g., NASH), which is less invasive and highly sensitive and which can be performed in a simple manner. According to the method, the level of a mitochondrion-derived protein (e.g., ornithine carbamoyltransferase or glutamate dehydrogenase) of a blood sample from a patient suffering metabolic syndrome and/or non-alcoholic fatty liver disease is measured, and the measured protein level is compared with an averaged value of protein levels of healthy volunteers, whereby whether or not the patient has a hepatic disorder (e.g., NASH) is determined.04-30-2009
20100323380METHODS FOR DIAGNOSING BLOOD VESSEL REOCCLUSION - The present invention features a method of diagnosing blood vessel reocclusion in a subject by detecting increased levels of sFLT-1 in a biological sample from the subject.12-23-2010
20090035796Enzyme sensors including environmentally sensitive or fluorescent labels and uses thereof - Sensors for detecting enzyme activity are provided. The sensors include substrate modules having environmentally sensitive labels and detection modules whose binding to the substrate modules results in changes in signals from the environmentally sensitive labels or polypeptides or polypeptide substrates including environmentally sensitive or fluorescent labels. Compositions including substrate modules, polypeptides, or polypeptide substrates and nucleic acids encoding enzymes and/or detection modules are also described. Methods of assaying enzyme activity using sensors including environmentally sensitive or fluorescent labels are provided, as are related methods for screening for modulators of enzyme activity.02-05-2009
20110244496HIV REVERSE TRANSCRIPTASE COMPOSITIONS AND METHODS - The present invention provides engineered novel variants of human immunodeficiency virus reverse transcriptase (HIV-RT) capable of being expressed in large quantity and that with polymerase and RNase H activity in a form that facilitates crystallization and high resolution structure resolution following X-ray diffraction. The present invention facilitates high resolution determination of RT in complexes with RT drugs and RT inhibitors, and provides methods for systematic generation of variants and for structure based identification and design of novel RT inhibitors.10-06-2011
20100028921RISK STRATIFICATION FOR ACUTE CORONARY SYNDROME BY MEANS OF FRAGMENTS/PARTIAL PEPTIDES OF PROVASOPRESSIN, ESPECIALLY COPEPTIN OR NEUROPHYSIN II - The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.02-04-2010
20110244498TYROSINE KINASE-INDUCIBLE DOMAINS - The present invention relates to a tyrosine kinase-inducible domain (pKID) and uses thereof. An isolated polypeptide comprising the pKID, and an isolated polynucleotide comprising a nucleic acid sequence encoding the pKID are provided. Also provided are methods for determining tyrosine kinase and/or phosphatase activity in a sample and for identifying an agent that inhibits a tyrosine kinase or phosphatase using a polypeptide comprising the pKID.10-06-2011
20110244497METHOD FOR JUDGING SUSCEPTIBILITY OF CANCER CELLS TO ANTHRACYCLINE ANTICANCER AGENT AND COMPUTER PROGRAM - The present invention provides a method for judging susceptibility of cancer cells contained in a biological sample to an anthracycline anticancer agent comprising steps of: measuring expression levels of GST-π of cancer cells contained in a biological sample; and judging the susceptibility of cancer cells contained in a biological sample to an anthracycline anticancer agent as high when the expression level of GST-π obtained by the measuring process is high, and a computer program which makes a computer execute the method.10-06-2011
20100055725SYSTEM FOR ASSAYS OF AMINOTRANSFERASE - An assay system (03-04-2010
20100068743Method for predicting response of cancer patient to anticancer drug treatment - A method predicts a response of a cancer patient to anticancer drug based on a cell cycle profile score obtained by analyzing a malignant tumor of the cancer patient, wherein the method can predict a disease outcome including a complete response, a partial response, stable disease, no response, and time to progression of disease as patient's response to anticancer drug therapy.03-18-2010
20100068741ASSAY SYSTEM FOR ADENOSINE TRIPHOSPHATE AND CREATINE KINASE - An assay method includes providing a luminescent nanocrystal; combining a solution having an adenosine triphosphate molecule; and displaying a light emission by the luminescent nanocrystal and the solution combined.03-18-2010
20090215099METHOD OF IDENTIFYING CANCER BIOMARKERS AND CANCER PROGRESSION - An efficient method for identifying important cancer biomarkers and identifying progression of bladder cancer using pro-u-PA as a clinical tool is provided. Searching for biomarkers critical for bladder carcinoma diagnosis and prognosis, secreted proteomes of highly malignant U1 and pre-malignant U4 cell lines are first analyzed. Proteins in the cultured media of the U1 and U4 cell-lines were systematically examined by SDS-PAGE combined with MALDI-TOF mass spectrometry. Expression of pro-u-plasminogen activator (pro-u-PA) was confirmed by Western blot analysis and further evaluated. A statistically significant relationship between the low level and absence of pro-u-PA in urine with high stages and grades of the tumor samples was established. Constitutive expression of Ras dominant negative protein led to increased expression of pro-u-PA in cultured media, indicating the loss of pro-u-PA is associated with oncogenic transformation. The loss of pro-u-PA in urine has been identified as a marker of more advanced bladder carcinoma.08-27-2009
20110081671VASCULAR MARKERS IN THE REMODELING OF CARDIAC INJURY - The present invention is concerned with diagnostic means and methods. More specifically, the present invention relates to a method for diagnosing the angiogenic status of a subject suffering from myocardial infarction comprising determining the amounts of P1GF, sFLT1 and endoglin in a first sample of a subject obtained after myocardial infarction and in a second sample of the subject obtained after the first sample and comparing the amounts in the first sample with those in the second sample whereby the angiogenic status is diagnosed. The present invention also encompasses a method of determining whether a subject suffering from myocardial infarction is susceptible to a pro-angiogenic therapy. Finally, the present invention relates to a kit or a device for carrying out the method of the invention.04-07-2011
20110212474ABNORMAL ALTERATIONS OF PKC ISOZYMES PROCESSING IN ALZHEIMER'S DISEASE PERIPHERAL CELLS - The present invention provides a method for the diagnosis of AD from non-AD conditions by using a PKC Isozyme Index obtained by determining ratios of ratios of different PKC Isozymes in peripheral cells of a test subject in the absence and presence of a beta-amyloid peptide, and optionally, in the presence of a PKC activator.09-01-2011
20110045515METHOD TO DETECT HEMOLYTIC STREPTOCOCCUS AND OPTOELECTRICALLY DETERMINE RESULTS - A reagent is provided for the detection of an exotoxin protein produced by a betahemolytic 02-24-2011
20110045514METHODS FOR DETECTING MAJOR ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS - The present teachings relate to a method of assessing the probability of a major adverse cardiovascular or cerebrovascular event in a human. The method can include measuring a concentration, in a blood-based sample of a human, of a set of analytes, for example, alpha-fetoprotein, cancer antigen 125, glutathione S-transferase, and tissue factor. The method also can include determining a MACCE index for the set of analytes and identifying the human as having an increased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is greater than zero, or a decreased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is less than or equal to zero.02-24-2011
20090023169High throughput sarcomeric assay - The present invention provides high throughput screening systems for identifying compounds that modulate the biological activity of a biochemically functional sarcomere. The method can be performed in plurality simultaneously with fluorescence or absorbance readouts.01-22-2009
20090317850Crystal Structure of Human 70KD Ribosomal Protein S6 Kinase 1 Kinase Domain - Crystallization of the 70 kDa ribosomal protein S6 kinase polypeptide 1 (p70S6K1) kinase domain for X-ray crystallography analysis to generate the three-dimensional structure of the p70S6K1 kinase domain is described. Further described is the use of the three 5 dimensional structure of p70S6K1 kinase domain for identifying and designing ligands or low molecular weight molecules that specifically bind to and modulate (inhibit) the kinase activity of p70S6K1. These ligands or molecules can be used for the treatment of metabolic disorders such as diabetes and for the treatment of various cancers.12-24-2009
20090317849BIOCHIP FOR THE DETECTION OF PHOSPHORYLATION AND THE DETECTION METHOD USING THE SAME - The present invention relates to a biochip for the detection of phosphorylation and a detection method of phosphorylation using the same, more precisely a biochip prepared by integrating a recombinant fusion protein produced from the reaction of a kinase matrix selected from the group consisting of PKC (Protein Kinase C), cc2-PK (cdc2 Protein Kinase) and DNA-PK (DNA-dependent Protein Kinase) and the elevated protein Selenomonas ruminantium membrane protein on a substrate coated with an active group, a detection kit of phosphorylation composed of the said biochip and a cofactor labeled with a radio-isotope and a detection method of phosphorylation using the same. The biochip for the detection of phosphorylation of the present invention using a radio-isotope facilitates the detection of phosphorylation with a minimum amount of a sample by simple processes, compared with the conventional method using an antibody. Since this method can analyze a large amount of samples in a shorter period of time, it can be effectively used for the analysis of kinase activity.12-24-2009
20090246810Use of MRP 8/14 levels for discrimination of individuals at risk of acute coronary syndromes - The present invention relates to a method for determining the risk whether an individual showing at least one symptom of an evolving acute coronary syndrome (ACS) is suffering from an acute coronary syndrome comprising the steps of (a) measuring, preferably in vitro, the level of MRP 8/14, wherein (b) if the level of MRP 8/14 is at least increased, then the individual is at risk of suffering from an acute coronary syndrome. The invention further relates to methods for ruling out whether an individual showing at least one symptom of an evolving ACS is suffering from an ACS, for assessing whether an individual showing at least one symptom of an evolving ACS is not at risk of suffering from an ACS and to discriminate if an individual showing at least one symptom of an evolving ACS is at risk to suffer from an ACS and or has no ACS.10-01-2009
20100311093METHOD OF AMPLIFYING ATP AND USER THEREOF - The ATP amplification method is a method for amplifying and detecting a very trace amount of exogenous ATP by allowing a fusion protein (PPK-ADK) of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP, to act on a mixture of ATP, AMP, and a polyphosphate compound. Also provided is an ultrasensitive ATP amplification method by which ATP at a single cell level can be amplified and detected, and an ultrasensitive microbial assay based on this ATP amplification method.12-09-2010
20090047695MICRODEVICES FOR HIGH-THROUGHPUT SCREENING OF BIOMOLECULES - Methods and devices for the parallel, in vitro screening of biomolecular activity using miniaturized microfabricated devices are provided. The biomolecules that can be immobilized on the surface of the devices of the present invention include proteins, polypeptides, nucleic acids, polysaccharides, phospholipids, and related unnatural polymers of biological relevance. These devices are useful in high-throughput drug screening and clinical diagnostics and are preferably used for the parallel screening of families of related proteins.02-19-2009
20100323379SLEEP APNEA - This document relates to methods and materials involved in diagnosing sleep apnea and assessing the effectiveness of a treatment for sleep apnea. For example, methods and materials for using markers to determine whether or not a mammal (e.g., a human) has sleep apnea are provided. In addition, methods and materials that can be used to determine whether or not a mammal (e.g., a human) responds to a sleep apnea treatment are provided.12-23-2010
20080213812Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression - Methods and compositions are provided for modulating, e.g., increasing or decreasing, the expression of telomerase reverse transcriptase (TERT). In the subject methods, the binding interaction of the TERT Site C repressor site with a Site C repressor protein complex made up of one or more proteins is modulated to achieve the desired change in TERT expression. A feature of the subject invention is that the target Site C repressor protein complex includes an LSF protein. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic applications; therapeutic agent screening applications; and the like.09-04-2008
20080213810Screening Method for Hiv Rt Inhibitors - The present invention is directed to methods for identifying a specific class of inhibitors of HIV reverse transcriptase that act differently from known reverse transcriptase inhibitors. In particular, the invention is based on identifying inhibitors which have higher inhibitory activity in presence of a nucleoside triphosphate or pyrophosphate.09-04-2008
20120202234METHODS AND COMPOSITION FOR ISOPRENOID DIPHOSPHATE SYNTHESIS - Provided herein are methods and compositions relating to the synthesis of isoprenoid diphosphates using a mutated isopentenyl phosphate kinase.08-09-2012
20120202233Methods and uses of KSR kinase, and mutations thereof - Mutant KSR proteins are disclosed. The mutants include single amino acid substitutions, leading to either a loss of kinase activity or a loss of scaffolding activity. Also disclosed are methods of screening compounds for inhibitors of KSR kinase activity or KSR scaffolding activity. In some embodiments, the screening methods include protein complementation assays in which nucleic acids encoding fusion constructs comprising enzyme portions and kinase dimerization domains are expressed in cells. Inhibitors of dimerization can be indicated by loss of enzyme activity.08-09-2012
20110020853COMPOSITIONS AND METHODS FOR DETECTING PHOSPHOMONOESTER - The invention provides a method of modifying a phosphomonoester moiety of a target compound. The method can include the steps of (a) providing a target compound having an electrophilic moiety and a phosphomonoester moiety; (b) contacting the target compound with a first carbodiimide compound under conditions for preferential addition of the first carbodiimide compound to the electrophilic moiety over the phosphomonoester moiety, thereby forming an electrophile-protected target compound; and (c) contacting the electrophile-protected target compound with a second carbodiimide compound and a nucleophilic compound under conditions for addition of the nucleophilic compound to the phosphomonoester.01-27-2011
20100285511TRANSFORMED CELL WITH ENHANCED SENSITIVITY TO ANTIFUNGAL COMPOUND AND USE THEREOF - The present invention provides a transformed cell in which a polynucleotide having a nucleotide sequence encoding an amino acid sequence of an osmosensing histidine kinase having no transmembrane region is introduced in a functional form into a cell deficient in at least one hybrid-sensor kinase, a method of assaying the antifungal activity of a test substance using the transformed cell, and a method of searching an antifungal compound using the method, and the like.11-11-2010
20100216176NOVEL METHOD FOR SEQUENCE DETERMINATION USING NMR - The invention relates to methods for analyzing polysaccharides. In particular, compositional and sequence information about the polysaccharides are derived. Some methods use NMR in conjunction with another experimental method, such as, capillary electrophoretic techniques for the analysis.08-26-2010
20090176263Canis sphingosine 1-phosphate receptort isoform 107-09-2009
20110262944CONSTRUCTION AND CRYSTALLIZATION OF EXPRESSION SYSTEM FOR RNA POLYMERASE PB1-PB2 PROTEIN DERIVED FROM INFLUENZA VIRUS - The present invention aims to express influenza virus RNA polymerase on a large scale, to crystallize the influenza virus RNA polymerase, and to provide a method for screening a substance capable of serving as an active ingredient in anti-influenza drugs.10-27-2011
20110262943REAGENT KIT FOR MEASURING FRESHNESS - A reagent kit for measuring freshness, which can be stored at a relatively high temperature with high storage stability, is obtained by lyophilizing reagent solutions each containing a plurality of enzymes and an enzyme protecting agent. The reagent kit includes a first reagent and a second reagent. The first reagent is obtained by drying a frozen product of a first reagent solution containing XOD, NP, an enzyme protecting agent, and a color former under reduced pressure at a temperature not higher than the glass transition temperature (Tg). The second reagent is obtained by drying a frozen product of a second reagent solution containing XOD, NP, AP, an enzyme protecting agent, and a color former under reduced pressure at a temperature not higher than the glass transition temperature (Tg). The enzyme protecting agent is sucrose and/or gelatin, and the color former develops a color by conjugation with a reaction of decomposing Hx into xanthine and uric acid by XOD.10-27-2011
20100028922IDENTIFICATION AND CHARACTERIZATION OF HCV REPLICON VARIANTS WITH REDUCED SUSCEPTIBILITY TO BENZOFURANS, AND METHODS RELATED THERETO - The present invention provides methods of decreasing the frequency of emergence, decreasing the level of resistance, and delaying the emergence of a treatment-resistant Hepatitis C viral infection, by administering to a subject, either in combination or in series, an inhibitor of the Hepatitis C RNA-dependent RNA polymerase NS5B, e.g., a benzofuran, such as 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide (HCV-796), and at least one additional anti-Hepatitis C agent, e.g., a ribavirin product or an immunomodulator, such as an interferon product. Additionally, the invention relates to methods of monitoring the course of treatment of a Hepatitis C viral infection, methods of monitoring and prognosing a Hepatitis C viral infection, and methods of identifying an individual with a decreased likelihood of responding to an anti-Hepatitis C viral therapy. These methods use the sequence and/or structure of the Hepatitis C RNA-dependent RNA polymerase NS5B to identify the emergence of a treatment-resistant Hepatitis C viral infection, particularly a benzofuran (e.g., HCV-796) treatment-resistant Hepatitis C viral infection.02-04-2010
20100021949Method for Detecting Transferase Enzymatic Activity - Methods and kits for detecting transferase activity in a sample by measuring ATP using a composition comprising an ATP-dependent bioluminescence-generating enzyme, a luminogenic molecule and one or more transferase quenching agents.01-28-2010
20100068742Methods - A method for identifying a compound expected to be useful in modulating, for example inhibiting, LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates, for example inhibits, the protein kinase activity of a LRRK2 polypeptide on a substrate polypeptide and (2) selecting a compound which modulates, for example inhibits, the said LRRK2 polypeptide protein kinase activity, wherein the substrate polypeptide comprises the sequence (W/F/R/K)(W/F/R/K)(R/K)(F/W/H/R)(Y/W/R)(03-18-2010
20120040387METHOD AND REAGENT FOR MEASURING MEVALONIC ACID, 3-HYDROXYMETHYLGLUTARYL COENZYME A, AND COENZYME A - The present invention provides a method for measuring the concentration of an analyte in a test solution wherein the analyte is mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A, comprising the following steps (p) and (q): (p) a step of allowing an enzyme that catalyzes a reaction represented by Reaction Formula 1 and an enzyme that catalyzes a reaction represented by Reaction Formula 2 to act on a test solution containing mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A in the presence of a hydrogen acceptor X, a hydrogen donor Y, and coenzyme A; and (q) a step of measuring an amount of: a reduced hydrogen acceptor X that is produced; or an oxidized hydrogen donor Y that is produced; or a hydrogen acceptor X that is decreased; or a hydrogen donor Y that is decreased, wherein the hydrogen donor Y and the reduced hydrogen acceptor X are not the same.02-16-2012
20090215098QUANTIFICATION OF ENZYME ACTIVITY BY MASS SPECTROMETRY - The disclosure relates to methods of quantitatively analyzing the enzymatic activity of enzymes in samples containing a plurality of enzymes, using mass spectrometry. Isotopically labeled standards are employed. Purified enzymes and enzymes from crude cell lysates may be analyzed using the disclosed methods. As little as 0.02 pg of cell lysate may be detected. Also disclosed are kits for providing compositions so as to practice the disclosed methods.08-27-2009
20100297681FLUORESCENT PROBE FOR MEASUREMENT OF GLUCURONATE TRANSFERASE - A fluorescent probe for measurement of UDP-glucuronosyltransferase, which comprises a fluorescein derivative, wherein in the fluorescein derivative, the 2-carboxy group on the benzene ring of fluorescein is replaced with another monovalent substituent, provided that said substituent is a substituent other than sulfo group, and the substituent does not have carboxy group or sulfo group, and wherein the fluorescein derivative may have an arbitrary substituent at a position on the benzene ring other than the 2-position, and the fluorescein derivative may have a substituent selected from the group consisting of an alkoxy group and a halogen atom at the 2-position and/or the 7-position of fluorescein.11-25-2010
20090111133Gel Filtration Standard - A gel filtration standard suitable for use as molecular weight markers for gel filtration chromatography for a mobile phase with denaturant. In one embodiment, the gel filtration standard comprises ovalbumin, myoglobin, and vitamin B04-30-2009
20090136976Luminescence-based composition - Luminescence-based compositions for measurement of aspartate aminotranserase, alanine aminotransferase, total-bilirubin, creatinine phosphokinase, or lactate dehydrogenase, wherein the chemiluminescence-based composition comprises 0.01-100 mM of luminol, 0.001-1000 U/mL of horseradish peroxidase (HRP), 0-10% of Triton X-100, 0-100 mM PIP, and 5˜500 mM of buffer at pH 6˜9, and the luminescence-base composition measures Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or lactate dehydrogenase (LDH).05-28-2009
20090068693HIGH SENSITIVITY ASSAY FOR DETECTION OF NUCLEOSIDE DIPHOSPHATE PRODUCTION - The present invention provides assays for detecting ADP, GDP and inorganic phosphate. These assays can be used directly to detect the presence of ADP, GDP and inorganic phosphate or can be used as part of a number of methods for identifying candidate agents that bind to a target protein or serve as modulators of the biological activity of a target protein.03-12-2009
20090075312ASSESSING COLORECTAL CANCER BY MEASURING OSTEOPONTIN AND CARCINOEMBRYONIC ANTIGEN - The present invention relates to a method aiding in the assessment of colorectal cancer (=CRC). It discloses the use of a marker combination comprising osteopontin and carcinoembryonic antigen in the assessment of colorectal cancer. Furthermore, it especially relates to a method for assessing colorectal cancer from a liquid sample, derived from an individual by measuring at least the markers osteopontin and carcinoembryonic antigen in said sample. The marker combination comprising osteopontin and carcinoembryonic antigen can, e.g., be used in the early detection of colorectal cancer or in the surveillance of patients who undergo therapy, e.g., surgery.03-19-2009
20090068694Enzyme Activity Measurements Using Bio-Layer Interferometry - Disclosed are enzyme assays using biolayer interferometry. Assays may be carried out using immobilized substrate or with a substrate capture format. In certain embodiments, the assays are carried out using unlabeled substrates. The methods are broadly applicable to enzyme assay measurements, can be carried out in vivo or in vitro, and are easily multiplexed.03-12-2009
20120301909SULFOTRANSFERASE ASSAY - Assays and methods for detecting and/or quantifying activity of a test sulfotransferase comprising by releasing a free phosphate from the PAP produced by the sulfotransferase reaction and detecting the free phosphate. The assay can includes gPAPP, a free phosphate detector and an optional control sulfotransferase. The method includes combining a test sulfotransferase with the substrate of the sulfotransferase, PAPS and gPAPP and detecting the free phosphate. The level of free phosphate directly correlates to the activity of the sulfotransferase. The assay and methods can be used to screen agents for their effect upon sulfotransferase activity.11-29-2012
20090298105RECONSTITUTED HISTONE METHYLTRANSFERASE COMPLEX AND METHODS OF IDENTIFYI NG MODULATORS THEREOF - The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.12-03-2009
20090136977NOVEL TARGETS FOR ALZHEIMER'S DISEASE - Compositions and methods for post-translational modifications that include acetylCoA:lysine acetyltransferase activity in the ER lumen are provided. The disclosed compositions and methods are especially suited for the identification of compounds useful for the prevention or treatment of neurodegenerative diseases such as Alzheimer's.05-28-2009
20110318769METHOD AND COMPOSITION FOR TARGETING VICIOUS CYCLES OF STRESSES AND INFLAMMATORY RESPONSES - The present invention provides methods and compositions for targeting the pathologically relevant bipolar actions of these master integrators without affecting the basal physiologically relevant functions. NFA can be used as marker of vicious cycles. Partial inhibition of NFA will be less toxic (in most cases) and more efficient for simultaneous partial inhibitions of all key mediators to terminate this vicious cycles for prevention and treatment of the long-term stresses and chronic inflammation-related diseases without causing any side effects and complications. Aberrant expression of NFA, master stress, and inflammation integrators play a role in orchestrating of vicious cycles. Aspects of the invention provide core technology for simultaneously targeting 12 hallmarks of cancer.12-29-2011
20100227351 METHOD OF DETECTING AND SEPARATING SERUM GAMMA-GLUTAMYL TRANSFERASE (GGT) ISOFORMS IN A SAMPLE OF BIOLOGICAL FLUID AND THE ENZYME ISOFORMS THEREBY OBTAINED - A method is described for detecting the gamma-glutamyl transferase enzyme isoforms (GGT, EC 2.3.2.2) in a sample of biological fluid, such as for example plasma or serum. The method comprises an HPLC separation step of the sample proteins based on the molecular size and a second step for detecting the GGT isoforms by post-column reaction with a GGT enzyme substrate capable of generating a detectable final product, preferably by spectrophotometric or fluorimetric means. The GGT isoforms can be separated by ultra-centrifugation, thereby obtaining three enzymatic isoforms characterised by molecular weights of approximately 2000, 940, and 140 KDa, respectively.09-09-2010
20110318768METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT - The present invention provides a method for determining sensitivity of the tumor cells to an EGFR and/or HER12-29-2011
20120003676MASS SPECTROMETRY ASSAY FOR THIOPURINE-S-METHYL TRANSFERASE ACTIVITY AND PRODUCTS GENERATED THEREBY - Methods are described for measuring the amount of a methylation TPMT enzyme product in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying 6-MMP or isotopically labeled 6-MMP in a test sample utilizing mass spectrometric techniques and for using such methods to determine the activity of TPMT enzyme that is present in a sample.01-05-2012
20090023168Method of screening placental proteins responsible for pathophysiology of preeclampsia, and marker for early diagnosis and prediction of preeclampsia - The present invention relates to a method of screening placental proteins responsible for pathophysiology of preeclampsia, and a marker for early diagnosis and prediction of preeclampsia. In accordance with one aspect of the present invention, there is provided a method of screening placental proteins responsible for pathophysiology of preeclampsia by 2D E-proteomics analysis, comprising: isolating placental proteins from a placental tissue; separating the isolated proteins two-dimensionally through 2D electrophoresis; and comparing and analyzing the separated proteins based on scanned gel images and differences in the images between normal placental proteins and preeclamptic placental proteins, wherein the comparison and analysis of the placental proteins based on the scanned gel images and differences in the images are accomplished by selecting proteins with differences of 140% or more between two placentas.01-22-2009
20100112615GLYCOSYLTRANSFERASE ACTIVITY - We describe the production of nucleotide sugars other than uridine diphosphate glucose (UDP-glucose), for example UDP-rhamnose, and the use of these nucleotide sugars in the modification of acceptor molecules.05-06-2010
20110165603SMALL MOLECULE FLUORESCENT SENSORS FOR DETECTION OF POST-TRANSLATIONALMODIFICATIONS AND PROTEIN INTERACTIONS IN BIOASSAYS - The present invention relates to novel compounds which are capable as acting as fluorescent sensors or which are precursors for these and for the use of these for the assay of biological processes such as posttranslational modifications of biological molecules such as phosphorylation, de-phosphorylation, proteolytic cleavage, phosphodiesterase mediated hydrolysis of cyclic nucleotides, methylation, acetylation of proteins peptides, DNA, lipids and the detection of biomolecule interactions (e.g., protein-protein interactions). A small molecule sensor is described which can associate to phosphorylated biological targets via metal ion—phosphate association. The association event can be monitored as fluorescence quench, sensitized emission, fluorescence polarization or a combination thereof. The sensor is useful for determining enzyme07-07-2011
20110165601ASSAY SYSTEM - The present invention relates to materials and methods for performing assays directed to monitoring activity and function of intracellular components, such as proteins associated with organelles and other intracellular structures. In particular, the invention relates to permeabilised cell preparations and their use in studying activity of intracellular components, in particular for studying sarcoplasmic reticulum function.07-07-2011
20110165602EMISSION RATIOMETRIC INDICATORS OF PHOSPHOINOSITIDES - Emission ratiometric indicators of phosphoinositides comprise a fusion protein comprising a pleckstrin homology (PH) domain of Akt (also known as protein kinase B) and a “pseudoligand” containing acidic amino acid residues, which is sandwiched between resonance energy transfer (RET) pairs, such as cyan and yellow mutants of GFP (a FRET pair). Such indicators can be used, inter alia, to monitor spatiotemporal dynamics of phosphoinositides and in high throughput assays for inhibitors of PI3K, including drug screening assays.07-07-2011
20120058501OXIDIZED GLUTATHIONE ASSAY - The present invention provides an assay for detection of oxidized glutathione (GSSG).03-08-2012
20120064554METHODS FOR ASSAYING ENZYME ACTIVITIES - The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected.03-15-2012
20120208220METHOD AND KIT FOR DETECTING FOLTATE - A method and a kit for detecting folate are disclosed. The method includes the following steps: (a) mixing a sample and an extraction buffer to form a mixture, heating and then cooling the mixture, and separating a supernatant from the mixture by centrifugation; (b) adding a recombinant γ-glutamyl hydrolase (GGH) and a folate conversion enzyme to the supernatant to drive catalysis; (c) stopping the catalysis; and (d) analyzing the supernatant by high performance liquid chromatography.08-16-2012
20110065137Methods and Devices for Detecting Obstructive Uropathy and Associated Disorders - Methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.03-17-2011
20110065136Methods and Devices for Detecting Glomerulonephritis and Associated Disorders - Methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described.03-17-2011
20120252047SALICYLIC ACID DERIVATIVES WITH FLUOROPHORES AND METHOD OF MAKING AND USING THE SAME - A latent fluorophore is derived from salicylic acid, and containing a fluorogenic group and a moiety represented by formula I10-04-2012
20120122131SIMULTANEOUS DETECTION OF METABOLIC ENZYME ACTIVITY AND METABOLITE LEVELS - Provided are methods for detecting a metabolic disorder in an individual using mass spectrometry. One method involves (a) contacting a sample containing (i) a metabolically indicative enzyme and (ii) a metabolic analyte, with a substrate for the enzyme to produce a reaction admixture, under conditions wherein the enzyme is capable of acting on a corresponding substrate to generate a product, and wherein a protease inhibitor is present; (b) contacting the reaction admixture with a reagent that inhibits the ability of the enzyme to act on a corresponding substrate, wherein the metabolic analyte and the product are soluble in the reagent; to produce a test sample and (c) determining the presence or amount of the metabolic analyte and the product contained in the test sample using mass spectrometry, wherein a determined presence or amount of the metabolic analyte and the product correlates with presence or absence of the metabolic disorder.05-17-2012
20100248280Method for Identifying a Compound that Modulates Telomerase Activity - The present invention relates to a method for identifying compounds that modulate the activity of telomerase. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the TRBD, “thumb,” “finger,” and/or “palm” domain of telomerase and testing the compound for its ability to modulate the activity of telomerase.09-30-2010
20120164670METHODS AND KITS FOR MEASURING ENZYME ACTIVITY - The invention relates to methods and kits for measuring enzyme activity, including enzymes that produce nicotinamide.06-28-2012
20100173337QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS - Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.07-08-2010
20100173339PLATELET ACTIVATION MARKERS AS INDICATORS FOR ANTI-PLATELET THERAPY - Methods for determining the appropriateness of anti-platelet therapy in a patient with a platelet-affected disease. The Mean Platelet Component value in a patient blood sample is determined corresponding to the patient's platelet activation status. A high platelet activation status indicates the appropriateness of anti-platelet therapy.07-08-2010
20100173338Biomarkers for Cancer Sensitivity and Uses Thereof - Disclosed herein are biomarkers and uses thereof for evaluating anti-cancer efficacy and sensitivity.07-08-2010
20120077214Systems And Methods For Predicting Response To Minoxidil For The Treatment Of Androgenetic Alopecia - Methods, processes, systems, and apparatuses are disclosed for predicting minoxidil response in the treatment of androgenetic alopecia based on colorimetric assay.03-29-2012
20120315658AMELIORATION OF METABOLIC SYNDROME USING PHYSIOLOGICAL FUNCTIONS OF SPHINGOMYELIN SYNTHASE SMS2, OR SCREENING METHODS FOR AMELIORATING AGENTS - Disclosed is a method for screening for a medicinal agent that can decrease a body weight, a medicinal agent that can reduce a visceral fat, a medicinal agent that can reduce a triglyceride in the liver, and a medicinal agent that can ameliorate obesity and fatty liver. The method involves a step of measuring the inhibitory activity of a candidate substance on a sphingomyelin synthase, wherein the candidate substance is determined to have at least one function selected from the group consisting of an anti-obesity agent, a visceral fat-reducing agent, a fatty liver-treating agent and an adiponectin expression enhancer when the candidate substance has an inhibitory activity on the sphingomyelin synthase.12-13-2012
20120219978Method and System for Detection of Chloramphenicol - Fast and simple method of detecting the presence of chloramphenicol, a harmful compound if present in food products. The method makes use of a mutant chloramphenicol acetyltransferase (CAT) and a fluorophore-linked chloramphenicol in a system where chloramphenicol and the fluorophore-linked chloramphenicol competes for the active site of the mutant CAT. Because the fluorophore-linked chloramphenicol reduces its fluorescence upon binding to the active site and vice versa increases its fluorescence upon being displaced from the active site by the presence of unmodified chloramphenicol in a sample, the increase of fluorescence caused by a testing sample indicates the presence of chloramphenicol.08-30-2012
20120178116POLYPEPTIDES FOR IDENTIFYING FUNGICIDALLY ACTIVE COMPOUNDS - The invention relates to a combination of polypeptides from phytopathogenic fungi having the biological activity of an aurora kinase and the function of an aurora kinase activator, to nucleic acids coding therefore, to the use of the polypeptides and nucleic acids for identifying modulators of an aurora kinase, to processes for identifying such modulators and to the use of these modulators as fungicides.07-12-2012
20100009397SUBSTRATE-MIMETIC AKT INHIBITOR - Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionally homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterparts and are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors.01-14-2010
20100291607TRANSFORMED CELL WITH ENHANCED SENSITIVITY TO ANTIFUNGAL COMPOUND AND USE THEREOF - The present invention provides a transformed cell in which a polynucleotide having a nucleotide sequence encoding an amino acid sequence of an osmosensing histidine kinase having no transmembrane region is introduced in a functional form into a cell deficient in at least one hybrid-sensor kinase, a method of assaying the antifungal activity of a test substance using the transformed cell, and a method of searching an antifungal compound using the method, and the like.11-18-2010
20100291606SCREENING SYSTEM FOR DETECTING INHIBITORS OF HIV INTEGRASE-LEDGF/p-75 INTERACTION - The development and validation of a cell-based, homogeneous high throughput screening (HTS) assay for small compounds inhibiting the HIV integrase-LEDGF/p75 interaction is described herein. The HTS strategy has the potential to identify small-molecules interfering with the interaction of HIV integrase-LEDGF/p75. These small molecules represent starting scaffolds for therapeutic drug development.11-18-2010
20100291605ASSAYS FOR S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES - Disclosed are novel methyltransferase assay methods, comprising: including, in a reaction mixture for a methyltransferase activity, a purified or recombinant adenosine nucleosidase activity that catalyses release of an adenine or adenine derivative moiety from a transmethylation product, and a purified or recombinant adenine deaminase activity that catalyses deamination of the released moiety to hypoxanthine or respective derivative and ammonia, wherein the methyltransferase activity is rate-limiting; and determining the methyltransferase activity by spectrophotometric or chromatographic monitoring of the coupled deamination reaction products, or of subsequent enzymatic or chemical reactions coupled thereto. Coupled oxidation of the hypoxanthine to uric acid and hydrogen peroxide is optionally affected using purified or recombinant xanthine oxidase, wherein the methyltransferase activity is rate-limiting, and wherein determining the methyltransferase activity comprises monitoring of the coupled oxidation reaction. Variations are disclosed comprises monitoring of reaction products (e.g., to detect NH3, Hypoxanthine, H2O2, and Uric Acid).11-18-2010
20120264152DIAGNOSTIC AND PROGNOSTIC ASSAYS BASED ON CIRCULATING TYROSINE KINASE ACTIVITY - Provided herein are methods for the diagnosis, prognosis, or management of diseases, such as cancer, by measuring the tyrosine kinase activity in acellular body fluids. Further provided are methods of predicting response to therapy in certain populations of cancer patients by contacting an acellular body fluid sample from a patient with a test agent, such as a tyrosine kinase inhibitor, and then measuring the effect of the test agent on tyrosine kinase activity in the sample.10-18-2012
20120264151SYSTEM AND METHOD FOR DIAGNOSING LYMPHOMA IN CATS - The invention provides a method and a system for diagnosing lymphoma in cats. The system allows a care giver to measure the enzymatic activity of thymidine kinase in a blood sample. The invention teaches that when the enzymatic activity of thymidine kinase in the blood stream of a cat is above 15.5 Units per liter, the cat has a high probability of having lymphoma. The invention allows for initial diagnosis, follow up after treatment for lymphoma and/or monitoring for example in breeds that prone to have lymphoma.10-18-2012
20120258482PCNA METHYLTRANSFERASE - Proliferating cell nuclear antigen (PCNA)-dependent glutamate methyltransferases are disclosed that can methylesterify one or more glutamic acid or aspartic acid residues of PCNA.10-11-2012
20120258481CROSS-LINKING ATP ANALOGS - An adenosine 5′-triphosphate analogs modified at the gamma-phosphate with a reactive reagent. A method of forming the analog by activating a 4-amino benzoic acid, incubating the activated acid to obtain an amine, and coupling the amine with ATP in the presence of water soluble EDCI. A method of detecting the efficacy of a therapeutic by adding a gamma-phosphate modified ATP analog to a protein substrate, reacting the target proteins with the ATP analog, and analyzing the resulting cross-linked product, wherein the amount of product present correlates to the efficacy of the therapeutic is also provided.10-11-2012
20120190053Method of determining factor XIII with the aid of plasma-based reference material - The present invention is in the field of in-vitro diagnostics and relates to a method of determining the blood-clotting factor XIII (factor XIII, F XIII) with the aid of plasma-based reference material, and a test kit for carrying out the method.07-26-2012
20110124022METHODS FOR DETECTING PRE-DIABETES AND DIABETES - Non-invasive methods are provided herein for the diagnosis of pre-diabetes and diabetes using biomarkers identified in a biological fluid, such as saliva. These biomarkers can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.05-26-2011
20080299594Proteomic analysis of biological fluids - The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns the identification of the proteome of amniotic fluid (multiple proteins representing the composition of amniotic fluid) and the correlation of characteristic changes in the normal proteome with various pathologic maternal/fetal conditions, such as intra-amniotic infection, or chromosomal defects.12-04-2008
20110212475Fluorescently Or Spin-Labeled Kinases For Rapid Screening And Identification Of Novel Kinase Inhibitor Scaffolds - The present invention relates to a kinase labeled at an amino acid having a free thiol or amino group, wherein said amino acid is naturally present or introduced in the activation loop of said kinase, with (a) a thiol- or amino-reactive fluorophore sensitive to polarity changes in its environment; or (b) a thiol-reactive spin label, an isotope or an isotope-enriched thiol- or amino-reactive label, such that said fluorophore, spin label, isotope or isotope-enriched label does not inhibit the catalytic activity and does not interfere with the stability of the kinase. The invention furthermore relates to a method of screening for kinase inhibitor, a method of determining the kinetics of ligand binding and/or of dissociation of a kinase inhibitor and a method of generating mutated kinases suitable for the screening of kinase inhibitors using the kinase of the present invention.09-01-2011
20100203563Systems and Methods for Analyzing Persistent Homeostatic Perturbations - This invention is in the field of homeostasis analysis. More particularly, it relates to systems and methods for analyzing persistent homeostatic perturbations, i.e. chronic stress, by measuring levels of biomarkers that are related to chronic stress. This invention is also directed to systems and methods for analyzing the molecular mechanisms of chronic stress.08-12-2010
20100233743BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES - This invention relates to fluorescent probes for identification of compounds binding to protein kinases, for measurement of the affinity of inhibitors of protein kinases, and determination of the active concentration of protein kinases binding to the probe. Bisubstrate-analog character of the probe enables the simultaneous evaluation of inhibitors targeted to both ATP binding site and/or substrate protein/peptide binding domain of the kinase. High affinity of the probe (K09-16-2010
20120276567TALAROMYCES TRANSFORMANTS - The invention relates to a 11-01-2012
20110306074GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS - The present invention generally relates to materials and methods for exploiting glycosyltransferase reversibility for nucleotide diphosphate (NDP) sugar synthesis. The present invention provides engineered glycosyltransferase enzymes characterized by improved reaction reversibility and expanded sugar donor specificity as compared to corresponding non-mutated glycosyltransferase enzymes. Such reagents provide advantageous routes to NDP sugars for subsequent use in a variety of biomedical applications, including enzymatic and chemoenzymatic glycorandomization.12-15-2011
20110306073METHOD AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY AND SPECIFICITY OF METHYLTRANSFERASES - The invention provides crystalline O-methyltransferases and isolated non-native O-methyltransferases as well as sets of their structural coordinates. Also provided are methods of predicting the activity or substrate specificity of putative O-methyltransferases, methods of identifying potential substrates of O-methyltransferases, and methods of identifying potential inhibitors of methyltransferases.12-15-2011
20100209950GRANULOCYTE-BASED METHODS FOR DETECTING AND MONITORING IMMUNE SYSTEM DISORDERS - Methods are provided for determining a subject's susceptibility to an allergic reaction upon exposure to an offending allergen. Methods are also provided for determining and monitoring a subject's responsiveness to ongoing allergy treatment08-19-2010
20100093008PHOSPHO-SPECIFIC ANTIBODIES TO FLT3 (TYR969) AND USES THEREOF - The invention discloses a newly discovered Flt3 phosphorylation site, tyrosine 969 (Tyr969) in the intracellular domain, and provides reagents, including polyclonal and monoclonal antibodies, that selectively bind to Flt3 when phosphorylated at this site. Also provided are assays utilizing this reagent, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibody, that binds to Flt3 only when phosphorylated at Tyr969. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML).04-15-2010
20130011870Method For Assaying Diseases Characterized By Dyslipidemia - A method for diagnosing a disease or for evaluating the risk to develop a disease which is characterized by dyslipidemia in humans, in particular for diagnosing atherosclerosis, coronary heart disease, peripheral vascular disease, stroke, metabolic syndrome, diabetes (type I and II) and diabetes related sequale (diabetic polyneuropathy, diabetic retinopathie or diabetic nephropathie) as well as lipid associated neuropathies (like Charcot-Marie-Tooth neuropathies such as hereditary sensory and autonomous neuropathy type 1 (HSAN1)) by measurement of atypical products of serine palmitoyltransferase.01-10-2013
20100151506Chloroacetamidine Based Inhibitors and Activity Based Probes for the Protein Arginine Methytransferases - In accordance with certain embodiments of the present disclosure, a protein arginine methyltransferase inhibitor is provided. The inhibitor comprises an amino acid peptide joined to a chloroacetamidine warhead.06-17-2010
20080233603Fluorine NMR spectroscopy for biochemical screening - High-Throughput Screening (HTS) of large compound libraries is the method of drug-lead discovery. It is now well accepted that for a functional assay, quality is more important than quantity. A biochemical NMR method originally proposed by Percival and Withers (Biochemistry, 1992, 31, 498-505) is extended to the screening of Ser/Thr kinases. The method requires the presence of a CF09-25-2008
20080233602Detecting and profiling molecular complexes - Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex.09-25-2008
20080227131Signalling Assay and Cell Line - The invention relates to a sensor for indicating the transduction and inhibition of stress signals through the p38-MAPK pathway in living cells. The sensor comprises a reporter gene product and an isoform of p38 Mitogen Activated Protein Kinase (MAPK). The invention also provides plasmid and viral vectors containing nucleic acids encoding the sensor for the transfection of living cells. Stable cell lines expressing the sensor can be used in a live-cell or fixed-cell assay to measure activation or modulation of the pathway.09-18-2008
20080220462KIT FOR DETECTION OF HEMOLYTIC STREPTOCOCCUS - A reagent is provided for the detection of an exotoxin protein produced by a beta-hemolytic streptococcus bacteria suspected of being present in a host biological fluid collected from a subject. An enzyme inhibitor is present to inhibit rogue protein modification of the substrate to prevent a false positive result of the color change. A kit is provided that is readily usable by an untrained user and merely requires that an element of the kit be contacted with a biological sample and thereafter no further actions are required by the user before a discernable color change is observed with visible or UV light and a positive/negative results reference card.09-11-2008
20130130291Labelling of Fusion Proteins with Synthetic Probes - The invention relates to new proteins called alkylcytosine transferases (ACTs) derived from O05-23-2013
20090142785Capturing carrier, capturing device, analysis system using the same, and method for capturing and testing microorganisms - In order to make a process of capturing and testing air-borne microorganisms more convenient and quick, a capturing device which comprises the capturing carrier comprising a polymer which is in a gel phase at the time of capturing the microorganisms but undergoes a phase transition under heating to a sol phase at the temperature at or less than 40° C. (especially in the temperature range between 15° C. and 37° C.), and a vessel to contain the capturing carrier is used. Further, by comprising a test reagent in the polymer, the test reagent can be eluted upon said phase transition from a gel phase to a sol phase. By heating the capturing carrier, a phase transition to a sol phase can occur at or less than 40° C. As such, since recovery of microorganisms and addition of a test reagent to the microorganisms can be carried out simultaneously, the process can be simplified and the process time can be shortened.06-04-2009
20130143247VOLATILE ORGANIC COMPOUNDS FOR DETECTING CELL DYSPLASIA AND GENETIC ALTERATIONS ASSOCIATED WITH LUNG CANCER - The present invention provides methods of identifying a genetic abnormality such as mutation in EGFR or KRAS or ALK which is associated with the management of lung cancer or diagnosing, prognosing or monitoring the treatment of pre-cancerous conditions of the lung, such as bronchial dysplasia or atypical alveolar hyperplasia (AAH), through the detection of at least one volatile organic compound indicative of these states.06-06-2013
20110229917MULTIPLEX LIQUID TISSUE.TM. METHOD FOR INCREASED PROTEOMIC COVERAGE FROM HISTOPATHOLOGICALLY PROCESSED BIOLOGICAL SAMPLES, TISSUES AND CELLS - The invention provides methods for multiplex analysis of biological samples of formalin-fixed tissue samples. The invention provides for a method to achieve a multiplexed, multi-staged plurality of Liquid Tissue preparations simultaneously from a single histopathologically processed biological sample, where the protocol for each Liquid Tissue preparation imparts a distinctive set of biochemical effects on biomolecules procured from histopathologically processed biological samples and which when each of the preparations is analyzed can render additive and complementary data about the same histopathologically processed biological sample.09-22-2011
20130149729QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS - Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.06-13-2013
20110275103EMISSION RATIOMETRIC REPORTERS OF MEMBRANE PDK1 ACTIVATION - Phosphoinositide-dependent kinase 1 (PDK1) activity reporters can be used in high throughput assays for drug screening.11-10-2011
20110275102ACTIVATION OF MUTATED RAC-PK - The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor.11-10-2011
20130157299Tyrosine Kinome - Protein kinases are important signaling molecules involved in tumorigenesis. Mutational analysis of the human tyrosine kinase gene family (98 genes) identified somatic alterations in −20% of colorectal cancers, with the majority of mutations occurring in NTRK3, FES, GUCY2F and a previously uncharacterized tyrosine kinase gene called MCCK/MLK4. Most alterations were in conserved residues affecting key regions of the kinase domain. These data represent a paradigm for the unbiased analysis of signal transducing genes in cancer and provide useful targets for therapeutic intervention.06-20-2013
20110312005Enzymatic modification of cell-surface H antigen by glycosyltransferases - This invention relates to cells with modified blood group antigen expression. In particular, the invention relates to cells for use in haematology, immunohaemotology and immunology assays as serology controls.12-22-2011
20120028284TRAPPING COMPOUNDS AND METHOD FOR IDENTIFYING REACTIVE METABOLITES - A compound of formula (I) is useful to identify reactive metabolites.02-02-2012
20130203095METHOD OF SCREENING PLACENTAL PROTEINS RESPONSIBLE FOR PATHOPHYSIOLOGY OF PREECLAMPSIA, AND MARKER FOR EARLY DIAGNOSIS AND PREDICTION OF PREECLAMPSIA - The present invention relates to a method of screening placental proteins responsible for pathophysiology of preeclampsia, and a marker for early diagnosis and prediction of preeclampsia. In accordance with one aspect of the present invention, there is provided a method of screening placental proteins responsible for pathophysiology of preeclampsia by 2D E-proteomics analysis, comprising: isolating placental proteins from a placental tissue; separating the isolated proteins two-dimensionally through 2D electrophoresis; and comparing and analyzing the separated proteins based on scanned gel images and differences in the images between normal placental proteins and preeclamptic placental proteins, wherein the comparison and analysis of the placental proteins based on the scanned gel images and differences in the images are accomplished by selecting proteins with differences of 140% or more between two placentas.08-08-2013

Patent applications in class Involving transferase

Patent applications in all subclasses Involving transferase